PL2656860T3 - Preparaty środka zwężającego naczynia i sposoby ochrony komórek podczas chemioterapii i radioterapii przeciwnowotworowej - Google Patents

Preparaty środka zwężającego naczynia i sposoby ochrony komórek podczas chemioterapii i radioterapii przeciwnowotworowej

Info

Publication number
PL2656860T3
PL2656860T3 PL13157485T PL13157485T PL2656860T3 PL 2656860 T3 PL2656860 T3 PL 2656860T3 PL 13157485 T PL13157485 T PL 13157485T PL 13157485 T PL13157485 T PL 13157485T PL 2656860 T3 PL2656860 T3 PL 2656860T3
Authority
PL
Poland
Prior art keywords
radiotherapy
methods
cells during
cancer chemotherapy
during cancer
Prior art date
Application number
PL13157485T
Other languages
English (en)
Inventor
William E Fahl
Arnold E Ruoho
Minesh Mehta
Original Assignee
Wisconsin Alumni Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wisconsin Alumni Research Foundation filed Critical Wisconsin Alumni Research Foundation
Publication of PL2656860T3 publication Critical patent/PL2656860T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL13157485T 2005-06-17 2006-06-19 Preparaty środka zwężającego naczynia i sposoby ochrony komórek podczas chemioterapii i radioterapii przeciwnowotworowej PL2656860T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US69157105P 2005-06-17 2005-06-17
EP13157485.7A EP2656860B1 (en) 2005-06-17 2006-06-19 Topical vasoconstrictor preparations and methods for protecting cells during cancer chemotherapy and radiotherapy
PCT/US2006/023708 WO2006138691A1 (en) 2005-06-17 2006-06-19 Topical vasoconstrictor preparations and methods for protecting cells during cancer chemotherapy and radiotherapy
EP06773476.4A EP1890732B1 (en) 2005-06-17 2006-06-19 Topical vasoconstrictor preparations and methods for protecting cells during cancer chemotherapy and radiotherapy

Publications (1)

Publication Number Publication Date
PL2656860T3 true PL2656860T3 (pl) 2021-11-08

Family

ID=37570784

Family Applications (2)

Application Number Title Priority Date Filing Date
PL13157485T PL2656860T3 (pl) 2005-06-17 2006-06-19 Preparaty środka zwężającego naczynia i sposoby ochrony komórek podczas chemioterapii i radioterapii przeciwnowotworowej
PL06773476T PL1890732T3 (pl) 2005-06-17 2006-06-19 Preparaty zwężające naczynia krwionośne do podawania miejscowego i sposoby ochrony komórek podczas chemioterapii i radioterapii przeciwnowotworowej

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL06773476T PL1890732T3 (pl) 2005-06-17 2006-06-19 Preparaty zwężające naczynia krwionośne do podawania miejscowego i sposoby ochrony komórek podczas chemioterapii i radioterapii przeciwnowotworowej

Country Status (15)

Country Link
US (4) US8114914B2 (pl)
EP (2) EP1890732B1 (pl)
JP (4) JP5756250B2 (pl)
CN (3) CN101198362B (pl)
AU (1) AU2006261358B2 (pl)
CA (1) CA2611496C (pl)
DK (2) DK1890732T3 (pl)
ES (2) ES2675228T3 (pl)
HK (1) HK1245143A1 (pl)
HU (2) HUE038177T2 (pl)
IL (2) IL191869A (pl)
PL (2) PL2656860T3 (pl)
PT (2) PT2656860T (pl)
TR (1) TR201809015T4 (pl)
WO (1) WO2006138691A1 (pl)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9006175B2 (en) 1999-06-29 2015-04-14 Mannkind Corporation Potentiation of glucose elimination
JP4681231B2 (ja) 2002-03-20 2011-05-11 マンカインド コーポレイション 吸入装置
ATE486064T1 (de) 2004-08-20 2010-11-15 Mannkind Corp Katalyse der diketopiperazinsynthese
HUE025151T2 (en) 2004-08-23 2016-01-28 Mannkind Corp Diceto-piperazine salts for drug delivery
PT2656860T (pt) 2005-06-17 2021-07-28 Wisconsin Alumni Res Found Preparações vasoconstritoras tópicas e métodos para proteção de células durante a quimoterapia e a radioterapia do cancro
MX373000B (es) 2005-09-14 2020-05-21 Mannkind Corp Metodo para formulacion de farmaco basado en el aumento de la afinidad de agentes activos hacia las superficies de microparticulas cristalinas.
CN104383546B (zh) 2006-02-22 2021-03-02 曼金德公司 用于改善包含二酮哌嗪和活性剂的微粒的药物性质的方法
US8785396B2 (en) * 2007-10-24 2014-07-22 Mannkind Corporation Method and composition for treating migraines
MY155524A (en) 2008-06-13 2015-10-30 Mannkind Corp A dry powder inhaler and system for drug delivery
US8485180B2 (en) 2008-06-13 2013-07-16 Mannkind Corporation Dry powder drug delivery system
EP2609954B1 (en) 2008-06-20 2021-12-29 MannKind Corporation An interactive apparatus for real-time profiling of inhalation efforts
TWI494123B (zh) 2008-08-11 2015-08-01 Mannkind Corp 超快起作用胰島素之用途
EP2165706A1 (en) * 2008-09-18 2010-03-24 BioAlliance Pharma Treating Inflammatory Pain in Mucosa of the Oral Cavity Using Mucosal Prolonged Release Bioadhesive Therapeutic Carriers.
US8314106B2 (en) 2008-12-29 2012-11-20 Mannkind Corporation Substituted diketopiperazine analogs for use as drug delivery agents
US8538707B2 (en) 2009-03-11 2013-09-17 Mannkind Corporation Apparatus, system and method for measuring resistance of an inhaler
AU2010259943C1 (en) 2009-06-12 2016-03-03 Mannkind Corporation Diketopiperazine microparticles with defined specific surface areas
JP5784622B2 (ja) 2009-11-03 2015-09-24 マンカインド コーポレ−ション 吸入活動をシミュレートするための装置及び方法
RU2531455C2 (ru) 2010-06-21 2014-10-20 Маннкайнд Корпорейшн Системы и способы доставки сухих порошковых лекарств
MX353285B (es) 2011-04-01 2018-01-05 Mannkind Corp Paquete de blister para cartuchos farmaceuticos.
US20140343159A1 (en) * 2011-06-02 2014-11-20 Procertus Biopharm, Inc. Formulation of small adrenergic agonist salt forms in organic solvents
WO2012174472A1 (en) 2011-06-17 2012-12-20 Mannkind Corporation High capacity diketopiperazine microparticles
HK1201475A1 (en) 2011-10-24 2015-09-04 Mannkind Corporation Methods and compositions for treating pain
AU2013289957B2 (en) 2012-07-12 2017-02-23 Mannkind Corporation Dry powder drug delivery systems and methods
WO2014066856A1 (en) 2012-10-26 2014-05-01 Mannkind Corporation Inhalable influenza vaccine compositions and methods
BR112015023168B1 (pt) 2013-03-15 2021-08-10 Mannkind Corporation Composição de 3,6-bis(n-fumaril-4-aminobutil)-2,5-dicetopiperazina cristalina, método de produção de partículas de 3,6-bis(n-fumaril-4-aminobutil)-2,5-dicetopiperazina e uso de uma composição de dicetopiperazina cristalina
BR122019026637B1 (pt) 2013-07-18 2023-09-26 Mannkind Corporation Formulações farmacêuticas de pó seco e método para a fabricação de uma formulação de pó seco
CA2920488C (en) 2013-08-05 2022-04-26 Mannkind Corporation Insufflation apparatus and methods
US10307464B2 (en) 2014-03-28 2019-06-04 Mannkind Corporation Use of ultrarapid acting insulin
US10561806B2 (en) 2014-10-02 2020-02-18 Mannkind Corporation Mouthpiece cover for an inhaler
BR112017009980A2 (pt) 2014-11-14 2018-02-14 Follea Int ?sistema e método para prevenção de alopecia?.
WO2016201286A1 (en) 2015-06-11 2016-12-15 Applied Biology, Inc. Treatment of sexual dysfunction
EP3651767A1 (en) * 2017-07-14 2020-05-20 Galderma Research & Development Methods and compositions for reducing side effects in chemotherapeutic treatments
KR20200038506A (ko) * 2017-08-07 2020-04-13 핀치 테라퓨틱스, 인코포레이티드 건강한 장 장벽을 유지 및 회복시키기 위한 조성물 및 방법
EP3887351A4 (en) * 2018-11-27 2022-11-02 The Trustees of Columbia University in the City of New York COMPOUNDS, COMPOSITIONS AND METHODS FOR MODULATION OF FERROPTOSE AND TREATMENT OF EXCITOTOXIC DISORDERS
WO2021016081A1 (en) 2019-07-19 2021-01-28 Finch Therapeutics Holdings Llc. Methods and products for treatment of gastrointestinal disorders
WO2021084541A1 (en) * 2019-10-31 2021-05-06 Sol-Gel Technologies Ltd. Treatment of hair loss disorders with a topical egfr inhibitor
WO2023130086A1 (en) * 2021-12-31 2023-07-06 Jss Research, Llc Compositions and methods for topical treatment of vascular conditions
AU2022443966A1 (en) 2022-03-04 2024-08-22 Vasodynamics Limited Topical compositions and methods.
CN119313747B (zh) * 2024-12-17 2025-04-15 中国海洋大学三亚海洋研究院 一种鱼类表皮体色量化方法和装置

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2414918A (en) * 1941-09-23 1947-01-28 Abramson Harold Alexander Solutions for the improved nebulization therapy of the lungs and bronchioles
US2774789A (en) * 1947-10-24 1956-12-18 Sterling Drug Inc 1-arterenol and its acid-addition salts and preparation thereof
US2919230A (en) * 1953-10-29 1959-12-29 Rohm & Haas Hydrophilic base therapeutic compositions comprising cation-exchange resin
BE555319A (pl) * 1956-03-21 1900-01-01
US3039922A (en) * 1959-08-17 1962-06-19 Carter Prod Inc Method of administering tablets having decongestant and anti-histaminic activity
US3134720A (en) * 1962-06-27 1964-05-26 Bristol Myers Co Medicated gels
US3574859A (en) * 1968-07-05 1971-04-13 Carl M Kosti Process for the treatment of hypertrophied gums
GB2122892B (en) * 1982-07-02 1986-01-29 Squibb & Sons Inc Nystantin pastille formulation
SE457055B (sv) 1986-08-18 1988-11-28 Ferring Ab Topisk straalskyddsgel foer mukosa innehaallande kaerlsammandragande substanser
US4853216A (en) * 1987-04-02 1989-08-01 Bristol-Myers Company Process and composition for the topical application of alpha1 adrenergic agonist for pilomotor effects
US5256652A (en) * 1987-11-12 1993-10-26 Pharmedic Co. Topical compositions and methods for treatment of male impotence
US5013716A (en) 1988-10-28 1991-05-07 Warner-Lambert Company Unpleasant taste masking compositions and methods for preparing same
US5461042A (en) * 1988-12-30 1995-10-24 Loria; Roger M. Regulation of the immune system
US5374645A (en) * 1990-01-22 1994-12-20 Ciba-Geigy Corporation Transdermal administation of ionic pharmaceutically active agents via aqueous isopropanol
US5260292A (en) * 1991-03-05 1993-11-09 Marvin S. Towsend Topical treatment of acne with aminopenicillins
JPH04327533A (ja) 1991-04-23 1992-11-17 Lion Corp 抗アレルギー用粘膜局所投与剤
US5534242A (en) 1994-05-02 1996-07-09 Henry; Richard A. Lidocaine-vasoconstrictor aerosol preparation
US5585398A (en) * 1994-07-15 1996-12-17 Ernst; Amy A. Topical anesthetic comprising lidocaine, adrenaline, and tetracaine, and its method of use
NL9401183A (nl) 1994-07-19 1996-03-01 Nederland Ptt Modulator/demodulatorinrichting voor koppeling van een dataterminal met een zend/ontvanginrichting, alsmede werkwijzen voor het tot stand brengen van een dataverbinding tussen een eerste en een tweede modulator/demodulatorinrichting.
GB9422571D0 (en) 1994-11-09 1995-01-04 Whitehall Lab Ltd Haemorrihoidal compositions and method of use
CA2154979A1 (en) 1995-07-28 1997-01-29 Kenneth T. Armstrong Topical phenylephrine preparation
US5849761A (en) * 1995-09-12 1998-12-15 Regents Of The University Of California Peripherally active anti-hyperalgesic opiates
DE69735552T3 (de) 1996-12-23 2009-08-13 S.L.A. Pharma Ag Pharmazeutische zubereitung zur behandlung der analinkontinenz und analem juckreiz
GB2370989A (en) 2001-01-16 2002-07-17 Btg Int Ltd Piperine analogues for the treatment of skin conditions
US6284234B1 (en) * 1998-08-04 2001-09-04 Johnson & Johnson Consumer Companies, Inc. Topical delivery systems for active agents
JP2001131085A (ja) * 1999-08-25 2001-05-15 Saitama Daiichi Seiyaku Kk 経皮・経粘膜吸収用の医薬組成物
PL204106B1 (pl) * 2000-02-28 2009-12-31 Pharmakodex Ltd Zestaw do dostarczania środka terapeutycznego
US6375982B1 (en) 2000-07-05 2002-04-23 Capricorn Pharma, Inc. Rapid-melt semi-solid compositions, methods of making same and method of using same
US7510728B2 (en) 2000-10-06 2009-03-31 Takeda Pharmaceutical Company Limited Solid preparations
GB0028575D0 (en) * 2000-11-23 2001-01-10 Elan Corp Plc Oral pharmaceutical compositions containing cyclodextrins
US20030152637A1 (en) 2001-01-25 2003-08-14 Mark Chasin Local anesthetic, and method of use
DK1997478T3 (da) 2001-02-15 2013-12-09 Access Pharma Inc Flydende formuleringer til forebyggelse og behandling af slimhindesygdomme og -lidelser
US20040176359A1 (en) 2001-02-20 2004-09-09 University Of Kentucky Research Foundation Intranasal Benzodiazepine compositions
US20020192273A1 (en) 2001-06-15 2002-12-19 Teri Buseman Therapeutic patch useful for the treatment of hemorrhoids
US6585997B2 (en) * 2001-08-16 2003-07-01 Access Pharmaceuticals, Inc. Mucoadhesive erodible drug delivery device for controlled administration of pharmaceuticals and other active compounds
JP4544391B2 (ja) * 2001-12-28 2010-09-15 ライオン株式会社 眼科用組成物
US6919348B2 (en) * 2002-05-02 2005-07-19 Edward T. Wei Therapeutic 1,2,3,6-tetrahydropyrimidine-2-one compositions and methods therewith
US7439241B2 (en) 2003-05-27 2008-10-21 Galderma Laboratories, Inc. Compounds, formulations, and methods for treating or preventing rosacea
WO2005014524A2 (en) * 2003-08-07 2005-02-17 Wisconsin Alumni Research Foundation Amino thiol compounds and compositions for use in conjunction with cancer therapy
EP1656102A2 (en) 2003-08-21 2006-05-17 Transoral Pharmaceuticals, Inc. Compositions for delivering 5-ht agonists across the oral mucosa and methods of use thereof
US20070219253A1 (en) * 2003-09-17 2007-09-20 Gul Balwani Decongestant / antihistaminic / expectorant compositions
WO2005102334A2 (en) 2004-04-13 2005-11-03 Alza Corporation Apparatus and method for transdermal delivery of fentany-based agents
PT2656860T (pt) * 2005-06-17 2021-07-28 Wisconsin Alumni Res Found Preparações vasoconstritoras tópicas e métodos para proteção de células durante a quimoterapia e a radioterapia do cancro

Also Published As

Publication number Publication date
AU2006261358A1 (en) 2006-12-28
TR201809015T4 (tr) 2018-07-23
ES2675228T3 (es) 2018-07-09
EP2656860B1 (en) 2021-05-05
JP6348437B2 (ja) 2018-06-27
PT1890732T (pt) 2018-07-02
PT2656860T (pt) 2021-07-28
CN101198362B (zh) 2014-03-12
HK1200087A1 (en) 2015-07-31
JP2008543876A (ja) 2008-12-04
HK1245143A1 (zh) 2018-08-24
CN107496925A (zh) 2017-12-22
CA2611496A1 (en) 2006-12-28
EP1890732A4 (en) 2010-07-07
DK1890732T3 (en) 2018-07-02
HUE054887T2 (hu) 2021-10-28
US8247457B2 (en) 2012-08-21
EP1890732B1 (en) 2018-03-28
PL1890732T3 (pl) 2018-11-30
JP5756250B2 (ja) 2015-07-29
HUE038177T2 (hu) 2018-09-28
DK2656860T3 (da) 2021-07-26
US11197836B2 (en) 2021-12-14
US20070077219A1 (en) 2007-04-05
CN103948927A (zh) 2014-07-30
US8114914B2 (en) 2012-02-14
JP2018203788A (ja) 2018-12-27
AU2006261358B2 (en) 2012-05-31
JP2016155880A (ja) 2016-09-01
US20110218223A1 (en) 2011-09-08
WO2006138691A1 (en) 2006-12-28
ES2880624T3 (es) 2021-11-25
IL232904A0 (en) 2014-07-31
US20120316246A1 (en) 2012-12-13
IL191869A (en) 2014-06-30
EP1890732A1 (en) 2008-02-27
JP6473103B2 (ja) 2019-02-20
EP2656860A1 (en) 2013-10-30
IL191869A0 (en) 2011-08-01
CN103948927B (zh) 2017-11-07
JP2015098496A (ja) 2015-05-28
US20160136113A1 (en) 2016-05-19
CN101198362A (zh) 2008-06-11
CA2611496C (en) 2015-07-28
IL232904A (en) 2015-11-30

Similar Documents

Publication Publication Date Title
IL232904A (en) Blood Vessel Remedies and Cell Protection Methods for Chemotherapy and Cancer Therapy
WO2008054726A3 (en) Targeting nbs1-atm interaction to sensitize cancer cells to radiotherapy and chemotherapy
SG133592A1 (en) Methods for treating prostate cancer with herbal compositions
IL211861A0 (en) Methods and aparatus for providing ballistic protection
AU2003293194A1 (en) Compositions and methods for treating prostate cancer
IL185463A0 (en) Therapy of prostate cancer with ctla4 antibodies and hormonal therapy
EP1814544A4 (en) CANCER TREATMENTS
MXPA02010866A (es) Composiciones y metodos para proteger celulas durante la quimioterapia y radioterapia contra el cancer.
GB0418328D0 (en) Cancer methods and medicaments
AU2003258061A1 (en) Therapeutic inhibitionof protein kinases in cancer cells
IL176919A0 (en) Methods and compositions for treating cancer
IL182813A0 (en) Methods and systems for prognosis and treatment of solid tumors
EP2005954B8 (en) Kit for cancer therapy and pharmaceutical composition for cancer therapy
EP2137213A4 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF PROSTATE CANCER
EP1855662A4 (en) METHODS AND COMPOSITIONS FOR TREATING CANCER
EP1773883A4 (en) PRODUCTION OF ANTICANCER ANTIBODIES USING MASKED CANCER CELLS AS IMMUNOGENS
WO2006060819A3 (en) Dhmeq as a sensitizing agent for chemotherapy and immunotherapy of resistant cancer cells
AU2005339587A8 (en) Use of transcriptome-modifying agents and chemotherapy or radiotherapy against cancer
AU2003271457A1 (en) Methods for detecting prostate cancer
AU2002319792A1 (en) Polyamines and analogs for protecting cells during cancer chemotherapy and radiotherapy
HK1111914A (en) Antibody-immune cell ligand fusion protein for cancer therapy
HK1122507A (en) Methods and compositions for treating prostate cancer
AU2007901628A0 (en) Methods and compositions for treating prostate cancer
GB0405258D0 (en) Selective chemotherapy of malignant cancer cells
HK1110303A (en) Methods and compositions for treating cancer